Schering-Plough's announcement that it will acquire Organon BioSciences N.V., Akzo Nobel's human and animal health businesses including Intervet, for about EUR 11 billion ($14.4 billion). It names Panacur explicitly as an Intervet product.
Intervet's products include Nobivac, a range of canine vaccines; Panacur, a de-wormer; Bovilis, a bovine biological for disease control and eradication; and Nobilis, a poultry vaccine to keep flocks free from infectious disease.
Schering-Plough's announcement that it will acquire Organon BioSciences N.V., Akzo Nobel's human and animal health businesses including Intervet, for about EUR 11 billion ($14.4 billion). It names Panacur explicitly as an Intervet product. Neutral corporate disclosure, filed with the SEC as an exhibit to a Form 8-K (the press release itself is Schering-Plough copyright; the EDGAR copy is a US federal filing record). Transaction: approximately EUR 11 billion cash, $14.4 billion at the 9 March 2007 rate, expected to close by end-2007; Intervet 2006 sales about $1.5 billion; Boxmeer, Netherlands to be the headquarters of the combined animal-health business. Akzo Nobel's own announcement of the same deal is at akzonobel.com/for-media/media-releases-and-features/akzo-nobel-announces-intended-sale-organon-biosciences. Context: Panacur is the fenbendazole brand. Study type: news.
